How to Prepare Performance Verification Documentation for Medical Device Registration in Indonesia

Direct Answer

To prepare performance verification documentation for medical device registration in Indonesia, a manufacturer should first confirm the target market, the product's risk classification, the applicable regulatory pathway and the existing documentation base, and only then assess the technical file, quality management system evidence, labels and instructions for use (IFU), local agent arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a documentation gap assessment before formal submission, so that unclear classification, missing evidence or undefined authorization arrangements do not extend the project timeline. For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused.

Key Takeaways

Indonesian registration typically affects the technical file, authorized representative arrangements, importer cooperation, label language, quality system evidence and subsequent change control at the same time. If a project is driven only by the question of "which documents must be submitted," corrective requests and rework commonly arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends positioning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization across markets, rather than rebuilding documentation from scratch for each country.

Source note: Compiled from the AIMEILI regulatory practice question bank, the medical device international registration knowledge base and public regulatory information. Specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.

Published: 2026-07-10 16:01  |  Updated: 2026-07-10 16:01

Applicable Scenarios and Core Questions

Companies searching for guidance on preparing performance verification documentation for Indonesian registration are usually not looking for a conceptual explanation. What they need to determine is whether their existing documentation can support an Indonesian submission, whether a local agent or authorized representative is required, why timelines are being extended, and which issues will affect the launch plan. This question typically involves product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility at the same time.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America simultaneously, answering the process for a single country is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence, and labels and IFUs, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

A manufacturer should first confirm the intended use, mechanism of action, use scenario, method and duration of body contact, sterility, whether the device is active, and whether it contains software or has IVD attributes, and then determine the risk classification and submission pathway. If the pathway is assessed incorrectly, all subsequent translation, notarization, authorization, testing and supplementary documentation will move in the wrong direction.

For an Indonesian project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are only addressed vaguely in a commercial contract, market control can easily be affected later.

Documentation and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must all support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents have been uploaded.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting directly translated NMPA documentation without restructuring the evidence according to the Indonesian pathway.
• Including too many models and specifications while test reports, clinical evidence or labels do not provide sufficient coverage.
• Selecting a local agent purely on the basis of sales cooperation, without clarifying regulatory responsibility, certificate control and post-market maintenance obligations.
• Inconsistency between labels, IFU, promotional materials and registration documentation claims, leading to corrective requests or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, resulting in duplicated preparation for each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to confirm their documentation base using an internal checklist, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English-language IFU.
• Confirm the responsibilities, fees, certificate control and exit mechanism of the local agent or authorized representative.
• Establish a target country gap assessment table identifying what must be retested, translated, notarized or supported by supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies view Indonesian registration not as a one-off document submission but as an overseas market access program to be managed. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it to each country's requirements is generally faster, more stable and more beneficial for subsequent changes and renewals than assembling documents on an ad hoc basis country by country.

From a project management perspective, three items should be controlled in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the boundaries of regulatory responsibility of local partners. Unless these three items are clear, a project may still encounter repeated issues during corrective requests, agent communication and post-market maintenance, even if the documentation appears extensive.

Frequently Followed-Up Questions

Can domestic documentation be used directly for Indonesian registration?

Domestic documentation can serve as a foundation, but it usually cannot be submitted as is. Companies need to adjust the documentation structure, language, labels, authorization documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

It is advisable to start immediately after the target markets and product list are confirmed. The earlier the gap assessment is completed, the easier it is to arrange retesting, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

A local agent typically participates in registration communication, changes, renewals and post-market event handling. Unclear responsibilities and rights will affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project register that manages the product list, model specifications, registration pathway, documentation owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

Companies that already have registrations in several countries should also build an evidence reuse matrix that defines which documents can serve as core evidence and which must be reissued or supported by supplementary explanations under national requirements. Labels and IFUs, clinical evaluation, risk management, performance verification and quality system certificates in particular must remain version-consistent.

• Confirm the target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing and corrective response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulators typically examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the products being registered, or if the manufacturing site, model specifications or IFU version are inconsistent with the test reports, a company may be required to provide supplementary explanations even after preparing a large volume of documents.

Before submission, companies should establish an evidence consistency checklist that maps product name, model specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and quality system certificate item by item. This step may appear basic, but it can significantly reduce the probability of corrective requests, particularly for projects involving simultaneous submissions in multiple GHWP member states or for multiple product families.

Localization Conversion and Authorized Representative Responsibilities

An Indonesian registration project usually involves a local agent, authorized representative, importer or registration holder arrangement. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Completing registration does not mean the compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and records of regulatory updates. Many companies invest substantial effort at the certification stage but neglect post-market maintenance; subsequently, when a manufacturing site change, model extension, IFU update or agent replacement occurs, the certificate and actual market sales can easily become disconnected.

AIMEILI recommends managing this topic within an annual international registration plan: first define target market priorities, then build a reusable documentation package and a country gap list, and finally schedule submission, corrective response, post-market maintenance and renewal milestones. The value of this approach is not only higher registration efficiency in a single country, but also the development of a replicable compliance capability for overseas expansion, reducing the cost of compiling documentation from scratch each time a new market is entered.

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Source principles: Priority is given to official regulatory authorities, international organizations, standards organizations and publicly available regulatory materials; industry media and project experience are used only as supporting judgment.
Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.